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Abstract
When comparing time-varying treatments in a non-randomised set-
ting, one must often correct for time-dependent confounders that influence
treatment choice over time and that are themselves influenced by treat-
ment. We present a new two step procedure, based on additive hazard
regression and linear increments models, for handling such confounding
when estimating average treatment effects on the treated (ATT). The ap-
proach can also be used for mediation analysis. The method is applied to
data from the Swiss HIV Cohort Study, estimating the effect of antiretro-
viral treatment on time to AIDS or death. Compared to other methods
for estimating the ATT, the proposed method is easy to implement using
available software packages in R.
Keywords: additive hazards model, causal inference, linear increments
models, time-dependent confounding, treatment effect on the treated.
1 Introduction
The issue of time-dependent confounding is central in causal inference. When
comparing time-varying treatments in a non-randomised setting, one will often
need to correct for confounders that influence the treatment choice over time,
and that are themselves influenced by treatment. Such confounding can be
present in both clinical and epidemiological data, and requires a careful analy-
sis. The inverse probability weighted marginal structural Cox model has become
the most popular tool for handling such confounding in settings with time-to-
event outcomes (Robins et al., 2000; Sterne et al., 2005). The method identifies
a marginal estimate, where the effects of the time-dependent confounders on
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treatment are removed by inverse probability weighting procedures. Two other
general methods for handling time-dependent confounding has also been devel-
oped; g-computation (Keil et al., 2014; Westreich et al., 2012; Cole et al., 2013;
Edwards et al., 2014; Taubman et al., 2009) and g-estimation (Vansteelandt
et al., 2014a; Picciotto and Neophytou, 2016). All these three approaches fall
under the so called g-methods by Robins and co-authors (Robins and Hernán,
2009); see e.g. Daniel et al. (2013) for an introduction to these methods. Other
ways of dealing with time-dependent confounding has also been suggested, such
as the sequential Cox regression approach (Gran et al., 2010).
Treatment effects may be viewed in various ways and there are typically
more than one unique causal estimand that can be defined. The most common
methods used to adjust for time-dependent confounding, inverse probability
weighting and g-computation, are typically used to estimate the average total
treatment effect (ATE). Another causal contrast is the average treatment effect
on the treated (ATT). The ATT can in principle also be identified using existing
methods, and especially through g-estimation of structural nested models, but
this is hardly done in practice (Li et al., 2014; Vansteelandt et al., 2014a). The
reason is partly that it is not a straightforward method to implement, and, when
working with time-to-event outcomes, g-estimation is typically developed using
accelerated failure time models and not in a more traditional hazard regression
framework.
In this paper we present a new method for estimating the ATT, which is
based on combining two off-the-shelf methods; hazard regression models and
a method for modelling missing longitudinal covariate trajectories. We will
discuss the differences between the ATE and ATT effect measures for time-
varying treatments, when the latter can be of greater interest, and compare
results from methods estimating both quantities. The idea behind our proposed
method is to estimate the values that possible confounding processes would
have had if, counterfactually, a treated person had not been treated. If these
counterfactual values are substituted for the actual observed values, then, given
some assumptions, one can estimate the ATT. In other words, the causal effect
of treatment is estimated by modelling the treatment-free development of time-
varying covariates. We shall also show that our approach has an interesting
relationship to mediation, where quantities similar to natural direct and indirect
effects can be estimated from the analysis.
Note that the estimation of counterfactual values under the assumption of
no treatment has previously been applied in the two-stage approach of Kennedy
et al. (2010) and Taylor et al. (2014), although in a different setting than here.
There is also a relationship to the prognostic index discussed in Hansen (2008).
The proposed method is developed for additive hazards regression models
(Aalen, 1980, 1989). The method is applied to data from the Swiss HIV Cohort
Study, analysing the ATT of antiretroviral treatment on time to AIDS or death
for HIV patients. The method is also explored in a accompanying simulation
study. Incidentally, simulating data with time-dependent confounding in the
setting of additive hazards models it is quite simple, as opposed to using Cox
proportional hazards models (Havercroft and Didelez, 2012). The additive haz-
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ards model has generally been shown to be useful in causal settings because
it allows explicit derivations that are not available for the Cox model (Mart-
inussen et al., 2011; Martinussen and Vansteelandt, 2013; Vansteelandt et al.,
2014b; Tchetgen Tchetgen et al., 2015; Strohmaier et al., 2015). This is due
to collapsibility and other properties. The additive model also allows a more
explicit process approach which is important in causal inference (Aalen et al.,
2014). See Martinussen et al. (2016) for a recent application of instrumental
variables and the additive hazars model for estimating the ATT.
As with the popular inverse probability weighting approach, the suggested
method can also be said to be founded on the close relationship between the
issues of missing data and causal inference (Howe et al., 2015). When a treat-
ment is initiated, data that would have counterfactually been observed under no
treatment can be considered as missing. If these data were known, the causal
effect could be easily estimated. In this paper we use Farewell’s linear incre-
ments model (Farewell, 2006; Diggle et al., 2007) to estimate such missing data,
or more precisely, to estimate the missing covariate trajectories of the counter-
factual time-varying variables. When counterfactual covariate trajectories are
estimated, we will show that these can be used to give us an estimate of the
ATT.
The proposed method has the advantage of focusing specifically on individu-
als actually on treatment and estimating what they gain from it, both in terms
of the main outcome (survival) and intermediate time-dependent covariate tra-
jectories. In clinical practice the decision to set a patient on a treatment will
depend on specific criteria regarding whether the treatment is of use for the pa-
tient. When judging the effect of such a treatment it is natural to take this into
consideration, as is done when assessing the treatment effect for the actually
treated patients. Such an analysis clearly is a useful supplement to the average
treatment effect estimated in marginal structural models.
The basic idea behind the ATT is illustrated in Figure 1. The lower figures
on the left hand side illustrate a comparison between the two treatments applied
to the whole population; the average treatment effect (ATE). The lower right
hand figures give a similar comparison, but limited to the subgroup actually
on treatment; the average treatment effect on the treated (ATT). The idea and
estimation of treatment effect on the treated compared to average treatments
effects are discussed in many papers, and a good reference is that of Pirracchio
et al. (2013), where they point out that the ATT and ATE estimates may give
very different results and that the choice of method depends on the aims of the
analysis.
For time-varying treatments, which is the main concern in this paper, the
difference between the ATE and ATT becomes more complicated than in Figure
1. The ATE will then correspond to the treatment effect in a world where
treatment initiation is randomized at every time point, which again corresponds
to the average treatment effect in a counterfactual world where everyone is
observed under every possible time of treatment start (including never treated).
The ATT on the other hand, corresponds to the average effect of the treatment
regimes that were actually observed in the study population.
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Treated Untreated
Observed Two types of causal
treatment effects
vs.
ATE
vs.
ATT
Figure 1: Illustration of the actual observed population, compared to the coun-
terfactual target populations when estimating average treatment effects on the
treated (ATT) and average treatment effects (ATE).
Our causal model for estimating the ATT is spelt out in Section 2, while
Farewell’s linear increments model is formally introduced in Section 3. The
relationship to mediation is demonstrated in Section 4. In Section 5 we discuss a
shortcut through regression that yields an easier implementation of the method.
We also briefly discuss estimation in Cox proportional hazards models. The
application to the Swiss HIV Cohort data is found in Section 6, while results
from simulations are summaried in Section 7. A discussion is given in Section 8.
Details on the simulations and R code for carrying out the analyses, combined
with a package for Farewell’s linear increments model (Hoff et al., 2014), is
available in an online appendix.
2 A counterfactual additive hazards model for
the treatment effect on the treated
2.1 The causal estimand of interest
The target estimand in this paper is the ATT for a time-to-event outcome in
a setting with time-dependent exposure and confounding. Consider the illus-
tration in Figure 2, depicting the situation for a hypothetical individual that
starts treatment at some time point S. The time scale is time since inclusion
in the study. When treatment is started, we can imagine a counterfactual sce-
nario where treatment was not started at time S, and the individual remained
4
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0 S TSTS∗
On treatment
No treatment
Treatment start Potential event times
Actual
Counterfactual
Figure 2: Illustration of the counterfactual scenarios in terms of event times,
with S being the time of treatment initiation, TS the event time under the given
treatment and TS∗ the event time given no treatment. The black line denotes
the observed outcome and the red line the unobserved counterfactual, given that
treatment was never initiated.
untreated. Let TS be the potentially observed time of the outcome of interest
when treatment is actually started at time S and let TS∗ be the potential event
time in the counterfactual situation that treatment is not started at time S (or
later).
In order to achieve notational clarity, we express the hazard rates in terms
of conditional probabilities. Assume S = s and let h1(t; s) be the causal hazard
rate under the actual treatment initiation at s, for t ≥ s. We can then write
h1(t; s) = 1
dt
P (TS ≤ t+ dt |S = s, TS > t)
= E
[
1
dt
P (TS ≤ t+ dt |S = s, L1, TS > t) |S = s, TS > t
]
, (1)
where the second line in the formula follows from the Innovation theorem (Aalen
et al., 2008). Note that S = s represents conditioning, while T s is the result of
a do-operator; that is the survival time under do(treatment starts at s), where
S is a random variable. L1 is the value of the corresponding covariate process
under this same intervention.
Similarly, the causal hazard rate for the counterfactual scenario where treat-
ment is not started at s (or later), h0(t; s), can be written:
h0(t; s) = 1
dt
P (TS∗ ≤ t+ dt |S = s, TS∗ > t)
= E
[
1
dt
P (TS∗ ≤ t+ dt |S = s, L0, TS∗ > t) |S = s, TS∗ > t
]
, (2)
where TS∗ is the potential survival time under the intervention do(no treat-
ment). Notice that we still condition with respect to treatment start at time
S = s, but that counterfactually treatment is not started. The notation L0
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denotes the value of the covariate process in this case. The classic distinction in
causal inference between conditioning and intervention is important here. We
condition on treatment start at S, that is, we limit the outcomes to the part of
the sample space with this starting time. However, we then intervene to insure
that treatment is not really started.
The causal hazard difference is then given as follows for t ≥ s:
d(t; s) = h1(t; s)− h0(t; s). (3)
Defining the causal effect of interest, we integrate the causal hazard difference
over s to get a marginal effect. The effect will then only be a function of t, and
can be estimated. The average causal hazard difference is thus:
d∗(t) = E(d(t, S) | t > S) = ES(d(t, S)), (4)
which corresponds to the ATT for all observed versions of treatment, started
at any time point S. ES(.) denotes the conditional expectation given t > S,
computed over the distribution of S.
Note that, conceptually, this means that when treatment is started for an
individual, we want to create a "copy" of that individual who does not start
treatment and observe her or him under both scenarios. When looking at the
entire study population, this corresponds to a randomised study at treatment
start where randomisation determines whether the intended treatment is actu-
ally started or not. Hence, our target parameter d∗(t) is the average effect of
the treatment that was actually started, compared to no treatment.
2.2 Assumptions
We assume an additive hazards regression model for the event of interest, taking
the form
α(t;B,L) = δ(t)B(t) + γ0(t)c+ γ1(t)L1(t) + . . .+ γk(t)Lk(t), (5)
with parameters δ(t) and γm(t), for m = 0, . . . , k. Here, c denotes a vector of
baseline covariates, including a constant, and γ0(t) is a vector of time-dependent
coefficients. The covariate processes L(t) = (L1(t), . . . , Lk(t)) are various time-
dependent quantities that may influence or be influenced by treatment. These
processes are written as individual components and not in vector form since they
are the main focus of interest; they are assumed to be measured repeatedly over
time. The process B(t) indicates whether treatment has been started; it is equal
to zero with no treatment and changes to 1 when treatment starts. It is assumed
that once started, treatment continues, so B(t) cannot return to zero.
Assume that the model in Equation (5) is a causal model in the following
sense: If one manipulates (intervenes on) the processes L(t) or B(t), then the
parameter functions δ(t) and γ0(t), . . . , γk(t) in Equation (5) are assumed to stay
unchanged. This implies that the assumption of no unmeasured confounding is
met. For causal modelling in the setting of stochastic processes, see Røysland
(2012).
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Note that in our observed data, by definition, B(S) = 1, but we also imagine
a counterfactual scenario where B(t) was manipulated to be 0 for t ≥ S. In other
words, we consider the situation where the person on treatment was not actually
put on treatment and ask what would have happened then. The covariate pro-
cesses of this non-treated scenario, where treatment is not started at time S = s
or later, are denoted L0(t; s) = (L01(t; s), . . . , L0k(t; s)); these are unobserved
counterfactual quantities. We will therefore assume that we have a model for es-
timating these counterfactual individual covariate processes. The procedure we
use for doing so, which is based on Farewell’s linear increments model for miss-
ing longitudinal data, and the corresponding causal assumptions are described
in detail in Section 3. The covariate process under the scenario that treatment
is actually started at time S = s are denoted L1(t; s) = (L11(t; s), . . . , L1k(t; s))
and correspond to the actually observed processes L(t) for t ≥ s.
2.3 Identification
The additive structure of the model in Equation (5) leads to the following for-
mulation for the hazard rates in Equation (2) and (1):
h1(t; s) = δ(t) + γ0(t)c+ E
[
γ1(t)L11(t) + . . .+ γk(t)L1k(t) |S = s, TS > t
]
= δ(t) + γ0(t)c+ γ1(t)L˜11(t; s) + . . .+ γk(t)L˜1k(t; s), (6)
where L˜1i (t; s) = E
[
L1i (t; s) |S = s, TS > t
]
, and
h0(t; s) = γ0(t)c+ E
[
γ1(t)L01(t) + . . .+ γk(t)L0k(t) |S = s, TS∗ > t
]
= γ0(t)c+ γ1(t)L˜01(t; s) + . . .+ γk(t)L˜0k(t; s)
where L˜0i (t; s) = E
[
L0i (t) |S = s, TS∗ > t
]
.
The corresponding causal hazard difference in Equation (3) can then be
written as follows for t ≥ s:
d(t; s) = δ(t) + γ1(t)(L˜11(t; s)− L˜01(t; s)) + . . .+ γk(t)(L˜1k(t; s)− L˜0k(t; s)). (7)
When defining the causal effect, we shall integrate the causal hazard difference
over s to get a marginal effect. The effect will then only be a function of t, and
can be estimated. The average causal hazard difference is thus:
Using Equation (7) we can then identify the ATT in (4) using
d∗(t) =δ(t) + γ1(t)(ES(L˜11(t;S))− ES(L˜01(t;S)))
+ . . .+ γk(t)(ES(L˜1k(t;S))− ES(L˜0k(t;S))). (8)
2.4 Estimation
We will now discuss how to estimate the various components going into d∗(t).
Assume that a number of individuals, i = 1, . . . , n, participate in the study.
Let R(t) be the set of individuals for which Si < t, and who are still under
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observation (i.e. the event has not happened and no censoring has occurred).
Let r(t) denote the size of R(t) and assume that r(t) > 0 from time 0. For
simplicity, we assume independent censoring (see e.g. Aalen et al. (2008)), but
in the case of dependent censoring, one can also adjust for this using inverse
probability of censoring weighting.
First, the cumulative regression functions ∆(t) and Γ1(t), . . . ,Γk(t), defined
as the integrals from 0 to t of δ(t) and γ1(t), . . . , γk(t), are estimated with an
additive hazards model from all individuals, including those on and those off
treatment, using the actual observed L’s and treatment status. The estimates
are denoted by ∆ˆ(t) and Γˆ0(t), . . . , Γˆk(t).
Then, we estimate aj(t) = ES(L˜1j (t;S)). When t > S, then all individuals
are observed to be on treatment and hence an estimate is given as follows:
aˆj(t) =
1
r(t)
∑
i∈R(t)
Lj(t).
Note that we here make use of the consistency assumption, which means that
“a subject’s counterfactual outcome under the same treatment regime that he
actually followed is, precisely, his observed outcome” (Hernán et al., 2009).
Finally, we shall estimate
bj(t) = ES(L˜0j (t;S)). (9)
This is a counterfactual quantity, and shall be estimated by Farewell’s linear
increments model as described in Section 3. The resulting estimate is denoted
by bˆj(t). The estimated average cumulative causal effect based on Equation (8)
is then given by
Dˆ∗(t) = ∆ˆ(t) +
k∑
j=1
∫ t
0
(aˆj(u)− bˆj(u))dΓˆk(u). (10)
Since we only consider treated individuals and compare with individuals that
are identical apart from counterfactually not being on treatment, this is an
estimate for a treatment effect of the treated.
3 Estimating counterfactual covariate processes
when treatment is not started
So far we have shown how to estimate the causal effect of interest given that we
can impute estimates of the confounder processes in the counterfactual setting
that treatment had not been started. We shall view this as a missing data
problem (Howe et al., 2015). We now give a general description of Farewell’s
linear increments model and show how this model can be used to estimate the
missing counterfactual quantities.
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3.1 Farewell’s linear increments model
The linear increments model is a dynamic model for longitudinal data, analogous
to the counting process approach for survival data. The model was originally
suggested by Farewell (2006) and further described and discussed in Diggle
et al. (2007). It was designed to analyse, in a simple manner, missing data in
longitudinal studies. A multivariate generalisation of the model was given in
Aalen and Gunnes (2010). Applications include estimation of mean response
in studies with drop-out (Gunnes et al., 2009a) and correcting for missing data
when assessing quality of life in a randomised clinical trial (Gunnes et al., 2009b).
An R-package, FLIM, is available for fitting linear increments models (Hoff
et al., 2014).
Let us start by imagining the complete data set (i.e. without missing data):
Let K˜(t) be an n ×m matrix of multivariate individual responses defined for
a set of times t ∈ {0, . . . , j}, with K˜(0) = k0, where the matrix k0 contains
the fixed starting values for the processes. The number of columns in K˜(t)
corresponds to the number of m variables measured for an individual and the
number of rows corresponds to the number of n individuals.
We define the increment ∆K˜(t) = K˜(t) − K˜(t − 1) and assume, for each t,
that ∆K˜(t) satisfies the model
∆K˜(t) = K˜(t− 1)β(t) + ε˜(t), (11)
where β(t) is a m × m parameter matrix and ε˜(t) is an n × m error matrix.
The errors are defined as zero mean martingale increments such that E(ε˜(t) |
Ft−1) = 0, where Ft is the history of K(t) up to and including time t. It then
follows that
E(∆K˜(t) | Ft−1) = K˜(t− 1)β(t).
In analogy with censoring in survival analysis, missing data is common in
longitudinal data. Let ∆K(t) denote the actually observed increments, i.e.
when both components defining the increment are observed, and set ∆K(t)
equal to zero otherwise. The relation between the true and observed responses
and increments are ∆K(t) = Q(t)∆K˜(t), where Q(t) is a n×n diagonal matrix
defined as follows: For individual i, the i’th diagonal element of Q(t) is equal to
1 when the increment ∆K˜i(t) is observed and 0 otherwise. Let Qt denote the
history of the process Q(t), that is, up to and including time t.
3.2 Causal assumptions of the linear increments model
The key condition for proper modelling of missing longitudinal data using the
linear increments models is typically formulated trough the assumption of discrete-
time independent censoring (DTIC), as discussed in Diggle et al. (2007). This
assumption, which is analogous to the independent censoring assumption of sur-
vival analysis (see e.g. Aalen et al. (2008)), places constraints on the expected
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values of the increments ∆K˜(t) = K˜(t)− K˜(t−1) of the hypothetical response,
and can be formulated as follows:
E(∆K˜(t) | Ft−1,Qt) = E(∆K˜(t) | Ft−1), for all t.
The DTIC assumption has a close relationship to other no-confounders as-
sumptions, like sequentially missing at random (Seaman et al., 2016). In order
to follow the assumptions as formulated in counterfactual analyses from causal
inference, we will assume the slightly stronger condition of sequential conditional
exchangeability. This assumption can for the modelling of missing longitudinal
data be formulated as
∆K˜(t) ⊥ Q(t) | Ft−1,Qt−1, for all t
e.g. based on the definition in Hernán et al. (2009).
Sequential conditional exchangeability guarantees that the observed data
will satisfy the model defined in (11), so that we can write
∆K(t) = Q(t)K(t− 1)β(t) + ε(t).
3.3 Estimation of missing covariate values
The procedure for estimating missing covariate values is as follows: We assume a
nonparametric model over time, so that there is no assumed connection between
β(t1) and β(t2) for two different times t1 and t2. The parameter matrices β(t)
can then be estimated unbiasedly by the least squares approach from observed
increments, where we denote these estimates as βˆ(t). The least square estimate
of β(t) is given by
βˆ(t) = (UTU)−1UT∆K(t),
where U = Q(t)K(t− 1).
Now, let Q0(t) be an indicator which is equal to 1 when the value K˜(t) is
observed. The hypothetical complete predicted data values can be estimated
iteratively by (Aalen and Gunnes, 2010)
K˜est(0) = k0,
∆K˜est(t) = (1−Q0(t))K˜est(t− 1)βˆ(t) +Q0(t)(K(t)− K˜est(t− 1)), t = 1, . . . , j
(12)
K˜est(t) = K˜est(t− 1) + ∆K˜est(t), t = 1, . . . , j
given some initial values ko. Note that when observation takes place, the es-
timated value K˜est(t) simply equals K(t). When there is no observation, the
increments are updated according to the model.
Farewell’s linear increments model will now be used below for estimating
missing counterfactual values of covariate processes. For more details on the
properties of this model, see Diggle et al. (2007) and Aalen and Gunnes (2010).
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Figure 3: Illustrating the imputation of counterfactual covariate trajectories
by Farewell’s linear increments model. Black line illustrates observed covari-
ate trajectory and red line the originally unobserved, imputed counterfactual
covariate trajectory for a hypothetical individual.
3.4 Application to imputing counterfactual trajectories
The counterfactual values bj(t) from Equation (9) shall be estimated by Farewell’s
linear increments model. Assuming sequential conditional exchangeability, this
model can give us a precise prescription for how to model missing data, which is
central when estimating causal effects. Being exchangeable now means that the
risk of event among the untreated would have been the same as the risk of event
among the treated had subjects in the untreated group received the treatment
(and vice versa). In a longitudinal setting this means that "at every observation
time k and conditional on prior treatment and covariate history, the treated and
the untreated are exchangeable" (Hernán et al., 2009). This is also known as a
no unmeasured confounding assumption.
We shall apply the linear increments model to the process L. We then regard
the values prior to treatment start as observed. When treatment is started the
observations that would have been made in the absence of treatment are missing.
These are estimated by the iterative procedure in Equation (12). If treatment
is started at time s we thus estimate the quantity L˜0j (t; s) for each j. Taking
an average of these at time t over all individuals in R(t) gives an estimate
of bj(t). Notice from the definition of R(t) in Section 2.4 that estimation of
counterfactual trajectories will only take place until the individual is censored
or experiences an event in the observed data. An illustration of the imputation
idea is given in Figure 3.
An example showing how to impute counterfactual covariate values using
the linear increments models has recently been included in the R package FLIM
(Hoff et al., 2014).
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4 A mediation point of view
Mediation can also be studied for causal effects defined in an ATT setting, see
e.g. Vansteelandt and VanderWeele (2012). We shall show that the formula for
d∗(t) in Equation (8), can be interpreted as the sum of a direct effect on the
treated δ(t) and of an indirect effect transmitted through the covariates. This
can be made precise as follows:
The natural direct effect is the effect that would be observed if the mediator
under treatment was manipulated to be equal to the natural value of the me-
diator under no treatment. However, in our survival setting it is possible that
the individual might survive in one counterfactual world and not in the other
one, therefore manipulation at the individual level may not make sense. Instead
we can use the concept of randomized interventional analogues of natural di-
rect and indirect effects from VanderWeele (2015), see also standardized direct
effects in Didelez et al. (2006).
Consider individuals that have started treatment. According to Vander-
Weele (2015, Section 5.4.1); “we will consider what would have happened if we
fixed their mediator to a level that is drawn randomly from the subpopulation
that is unexposed. Thus instead of using the individual’s particular value for
the mediator in the absence of exposure, we use the distribution of the mediator
amongst all the unexposed”. Our procedure follows the same idea in a slightly
more general way, namely using the distribution of the mediator values among
those not on treatment to estimate values of the mediator for those on treat-
ment, where they not treated. This is precisely the calculation that is done by
Farewell’s linear increments model.
For the purpose of estimating average effects we can formulate this for ex-
pected values. Assume that the mediator is the set of all time-dependent co-
variates; hence, we assume that L1i (t; s) is manipulated to be equal to L0i (t; s)
for all i. The covariate part in Equation (8) would then be equal to 0, and so
we would have
d∗(t)dir = δ(t) (13)
as the average direct effect defined in the above sense. The average indirect
effect is defined as the difference between the total causal effect and the direct
effect; that is
d∗(t)indir = γ1(t)(ES(L˜11(t;S))− ES(L˜01(t;S)))
+ . . .+ γk(t)(ES(L˜1k(t;S))− ES(L˜0k(t;S))). (14)
A diagram illustrating a mediation model for k = 1 is shown in Figure 4.
The figure indicates that the causal effect may be seen as a sum of a direct
effect, and an indirect effect passing through the covariate; the latter being the
product of the coefficients on the two arrows.
Note that we have here a well defined composition valid at any time t. Based
on this we can estimate cumulative direct and indirect effects from Equation
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Covariate L
γ(t)
!!
Treatment B δ(t)
//
ES(L˜11(t;S))−ES(L˜01(t;S))
::
Event
Figure 4: Illustration of the mediation model for the causal effect of treatment
on a time to event outcome from Equation (13) and (14) in the simple case of
k = 1.
(10), that is:
Dˆ∗(t)dir = ∆ˆ(t), Dˆ∗(t)indir =
k∑
j=1
∫ t
0
(aˆj(u)− bˆj(u))dΓˆk(u). (15)
5 A shortcut through regression
A simple regression analysis can give us an approximate estimate of the causal
effect in Equation (10). To do such an analysis one only needs to manipulate
the values of the time-varying covariates in the original dataset, by giving indi-
viduals on treatment the imputed covariate values which they would have had,
if they were, counterfactually, untreated. The manipulated dataset can then be
analysed in a standard regression, adjusting for treatment, baseline covariates
and the partly manipulated time-varying covariates. The regression function for
the treatment covariate would then be the approximate estimate of the causal
treatment effect.
Why should this work? The idea is that if those on treatment are given
counterfactual covariates corresponding to no treatment, then the difference in
outcome between treated and untreated must be due to the treatment. The
same idea has worked well in the two-stage approach of Kennedy et al. (2010)
and Taylor et al. (2014). The setting of these papers are different but the basic
concept is the same.
5.1 The additive hazards model
The validity of the shortcut is best shown for additive models. We shall show
later, in simulations, that the results are very close to those found by the direct
approach in Section 2. However, we do not get exact theoretical results as we
did in Section 2.
To put it formally: For an individual starting on treatment at time s, the
hazard rate of an event from Equation (6) can be rewritten as follows for t ≥ s:
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h1(t; s) = δ(t) + γ0(t)c+ γ1(t)L˜11(t; s) + . . .+ γk(t)L˜1k(t; s)
= d(t; s) + γ0(t)c+ γ1(t)L˜01(t; s) + . . .+ γk(t)L˜0k(t; s)
For individuals not on treatment, that is, t < s, the hazard rate is given by
h(t; 0,L) = γ0(t)c+ γ1(t)L1(t) + . . .+ γk(t)Lk(t).
This is consistent with the following additive hazards regression model applied
to all individuals at risk:
µ(t) = γ0(t)c+ d(t, s)B(t) + γ1(t)L∗1(t, s) + . . .+ γk(t)L∗k(t, s),
where B(t) is the treatment indicator as defined earlier, and L∗i (t) equals L˜0j (t; s)
if B(t) = 1 and Li(t) if B(t) = 0. Note that for those on treatment we put in
counterfactual values of the covariates to mimic what they would have were
they not on treatment; this is the crux of the procedure. The causal effect
for an individual starting treatment at time s is seen to equal the coefficient
of the variable B(t). Note that this coefficient is dependent on the value of S,
and is hence random (i.e. varying between individuals). If we knew the values
of L˜0j (t; s) and could run this regression we would expect that the coefficient
corresponding to the covariate B(t) would be an average of the possible values,
and thus a reasonable estimate of d∗(t). Since we estimate the cumulative
coefficient in the additive regression model, we actually estimateD∗(t), denoting
this estimate D˜∗(t). This is an approximate procedure since the coefficient of
B(t) varies with the individual treatment starting time S, thus we have a varying
coefficient regression model. However, simulations show that D˜∗(t) is very close
to Dˆ∗(t) as might be expected. In fact, the simulations in Section 7 indicate
that the two approaches estimate almost exactly the same thing.
The procedure depends on estimating the L˜0j (t; s), which shall be done as
previously, using Farewell’s linear increments model. Since we have a precise
argument for Dˆ∗(t) and a less precise one for D˜∗(t), the first one might be seen
as more reliable. However, D˜∗(t) is slightly easier to compute and fits with ideas
already in the literature (Kennedy et al., 2010; Taylor et al., 2014).
5.2 The Cox model
Since the Cox model is the most common one in survival analysis, it is natural
to ask whether the present approach could be applied to this model as well.
The formal mathematical arguments in Section 2 and the causal effect given
in Equation (10) does not work in this case; however, the intuitive argument
given in Section 5 makes sense for the Cox model as well. Hence, one would
expect that the shortcut method might work for the Cox model. The hazard
rate would then be:
µ(t) = exp(γ0(t)c+ d(t, s)B(t) + γ1L∗1(t, s) + . . .+ γkL∗k(t, s))
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Again, we have a random coefficient model. What will be estimated by a Cox
model is some kind of average of the quantity d(t, s). Preliminary simulation in
Section 7.4 seems to indicate that this might give sensible results, but further
work on this issue is required.
6 Application to data from the Swiss HIV Co-
hort Study
Let us now consider data from The Swiss HIV Cohort Study (2010), study-
ing the effect of antiretroviral treatment (HAART) on time to AIDS or death.
The dataset we analyse consists of 2161 HIV infected individuals, with baseline
at the time of the first follow-up after January 1996. The data is organised
in monthly intervals, with time-varying variables describing the treatment re-
ceived, CD4 cell count, viral load (HIV-1 RNA), haemoglobin levels and other
relevant clinical variables. Scheduled clinical follow-up with protocol defined
laboratory tests takes place every sixth month and on average one additional
intermediate routine laboratory test is also recorded. In months with no new
observations, the last observation is carried forward. Baseline variables include
sex, year at birth, registration date and transmission category. The same dataset
has been analysed before in Sterne et al. (2005); Gran et al. (2010); Røysland
et al. (2011).
When estimating the effect of antiretroviral treatment on time to AIDS or
death, time-dependent prognostic factors such as CD4, viral load and haemoglobin
levels are typically time-dependent confounders. Time-dependent confounding
can be adjusted for using marginal structural models (see Sterne et al. (2005))
or the sequential Cox approach (see Gran et al. (2010)). We shall here apply
our new method for analysing the ATT.
Let us consider the three time-dependent variables CD4 count, viral load
and haemoglobin level. For all individuals in the dataset that started treat-
ment, we estimate their counterfactual covariate trajectories had they stayed
untreated, using the iterative procedure described in Section 3. The counterfac-
tual covariate values are estimated from the time treatment started and until
the individuals are censored or experience an event in the observed data. When
estimating counterfactual covariates, we adjust for baseline variables sex, age
at baseline, year at baseline and transmission category, together with the three
time-dependent variables. The observed and estimated covariate trajectories for
all untreated individuals are shown in Figure 5.
Figure 5 shows that over time untreated individuals experience a decrease
in CD4 and haemoglobin levels, and an increase in viral load. We see that
the estimated (light grey) covariate trajectories typically depict individuals who
are worse off, because they are modelled counterfactual trajectories, that is;
trajectories for individuals who have started treatment in the observed data.
This is best seen in the CD4 cell count trajectories because CD4 cell count is the
most important predictor of treatment initiation. Note that model uncertainty
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Figure 5: Observed (dark grey), estimated (light grey) and mean (black) CD4,
viral load (HIV-1 RNA) and haemoglobin trajectories for untreated individuals.
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gets bigger with time, as the size of the risk set decreases. This is seen by
the increasing fluctuations of estimated CD4 counts with time. Because of
this uncertainty the plots are truncated at 80 months, even though the last
observation was 92 months after the start of follow-up.
The effect of treatment on the time-dependent covariates themselves can be
studied graphically, by changing the time-scale to time since start of treatment
and plotting the two counterfactual regimes of treated and untreated together
(Figure 6). Here, the untreated group (the red lines) represent the unobserved
counterfactual covariate trajectories the treated individuals would have had if
they were not treated, which are all imputed values. For the treated group
(black and grey lines), imputations are only needed when patients are censored.
The rest of their trajectories are observed under treatment, as no individual, by
definition, goes from being treated to untreated.
In Figure 6 we clearly see the negative consequences for untreated patients;
lower CD4 counts and haemoglobin levels and higher viral load. Treated indi-
viduals, on the other hand, experience a rise in CD4 cell counts and a rather
rapid decline in viral load.
Let us now return to the main objective of adjusting for time-dependent
confounding. We want to estimate the treatment effect on the treated for an-
tiretroviral treatment on time to AIDS or death, using the method in Section
2. In practice, we impute values for all counterfactual time-varying covariates
under the scenario of no treatment, wherever these variables were not observed.
The only time-varying variable we do not alter is the treatment indicator, rep-
resenting the exposure we want to estimate, that is; the effect of treatment on
time to AIDS or death.
We use the shortcut approach in Section 5 since it was demonstrated in Sec-
tion 7 that it gives almost exactly the same result as the causal effect formula
(10). The analysis was carried out fitting an additive hazards model to a pseudo
dataset where all time-varying covariates for individuals on treatment were im-
puted using the linear increments model, adjusting for possible non-random
dropout using inverse probability of censoring weights. The included covari-
ates were HAART, sex, transmission category, baseline CD4 (sqrt cells per µL),
baseline RNA (log10 copies per mL), baseline haemoglobin (g per mL), baseline
CDC B event, previously experienced CDC B event at baseline, and current
CD4, RNA and haemoglobin. The data is grouped into monthly intervals and
baseline is set to the time of the first follow up visit after January 1996. For
the marginal structural additive hazards model, the same covariates were used,
except that the time-varying covariates were replaced by stabilised inverse prob-
ability of treatment weights. The applied censoring and treatment weights are
identical to the weights used in Sterne et al. (2005), which analysed the same
dataset.
Figure 7 (left panel) shows the cumulative treatment effect on the treated for
HAART versus no treatment, found using the approach in Section 5.1. Treat-
ment has a constant protective effect (a negative contribution to the hazard)
for the first 30 months, before the effect decreases. The plot is truncated at 50
months to give a more detailed picture of the initial phase. As a comparison, in
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Figure 6: Observed, estimated and mean CD4, viral load (HIV-1 RNA) and
haemoglobin trajectories for the two counterfactual regimes of treatment (black)
and no treatment (red).
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Figure 7: Analysis of the effect of HAART on AIDS or death in the Swiss HIV
Cohort Study comparing estimates of the treatment effect on the treated (left
panel) with average treatment effects (right panel). Both analyses are based on
additive hazards regression, the first imputing counterfactual covariate trajec-
tories from a linear increments model and secondly using an inverse probability
weighted marginal structural model.
the second panel of Figure 7, we include the cumulative coefficient for HAART
in a inverse probability weighted marginal structural Aalen additive model. This
is merely a weighted additive hazards model using the same inverse probabil-
ity of treatment and censoring weights as used in the marginal structural Cox
proportional hazards model in Sterne et al. (2005). We see from Figure 7 that
the estimated cumulative effects of treatment are somewhat smaller when using
the marginal structural model. This is reasonable, since one would expect those
actually treated to have a greater potential treatment effect on the average than
those not actually treated.
Tests of effect (i.e. testing for slope) may be carried out for the plots in
Figure 7, giving p = 0.0003 for the left panel and p = 0.002 for the right panel.
Note that robust confidence intervals are used for the curves in Figure 7.
The intervals in the left panel may be slightly too narrow, as the uncertainty in
the imputed values are not brought into the calculations of these intervals. An
alternative is to calculate confidence intervals by bootstrapping.
All analyses were done in R version 3.0.0, using the aareg function from the
package survival.
7 Simulation study
Let us now analyse simulated data to compare the methods and study their
behaviour. The methods we want to compare are the procedures based on
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imputation of counterfactual covariate trajectories for estimating ATT, inverse
probability weighted marginal structural models for estimating ATE and naive
methods that do not properly adjust for time-dependent confounding.
To generate data with time-dependent confounding we simulate event times
from an additive hazards model. We pretend to have a cohort of individu-
als under risk of experiencing some event of interest. Individuals are routinely
controlled to have a covariate value measured. The probability of starting treat-
ment on a specific time point will depend on an individual’s current covariate
value, and in return, starting treatment affects the future covariate process.
Both treatment status and the covariate value affect the probability of having
an event.
7.1 Data generation
Imagine a cohort of n individuals under risk of having an event E(t), which
can be postponed or prevented by treatment; everyone in the cohort starts
out untreated. Each individual has a time-varying covariate L(t) repeatedly
measured on a set of pre-specified time points t = 0, 1, ..., 11, given that they
have not yet experienced the event. To generate initial values of L(t) for each
subject, we took the square root of n numbers uniformly distributed on the
interval [25, 1000]. The range of the interval and the square root transformation
were employed to obtain a variable somewhat comparable to CD4 cell count.
Untreated, L(t) will decrease steadily, while when receiving treatment, L(t)
increase over time. Individuals who start treatment are not allowed to go back
to being untreated. The hazard of having an event within an interval [t, t+1) is
affected by treatment status B(t) and by covariate value L(t). Everyone enter
the study at t = 0, and those who have not experienced the event by t = 11 are
censored.
We will consider three different treatment regimes, which are summarised in
Figure 1 in the online appendix accompanying this paper. In the first, people
with low covariate values have a high probability of starting treatment. The
second regime is close to randomised treatment, meaning there are only small
differences between treated and untreated individuals in terms of covariate val-
ues. Finally, the last regime is the opposite of the first, i.e, individuals with
higher covariate values are prioritised for treatment. The online appendix also
contains a pseudo code algorithm for simulating data under these three treat-
ment regimes and the full corresponding R code. We ran the simulations 250
times, and in each run we generated a new dataset that was analysed with the
methods described in the following section.
7.2 Analysing simulated data
The simulated data is analysed with the procedures for estimating the ATT
as described in Section 2.4 and Section 5. For comparison, we also estimate
the ATE from a marginal structural additive hazards model and treatment ef-
fects from two naive approaches. Implementing the marginal structural model
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involves estimating weights based on the inverse probabilities of starting treat-
ment, which are then used in a weighted regression. The marginal structural
model does correct for time-dependent confounding, but unlike our methods,
the estimated effect of treatment is equivalent to comparing the effect of every-
one being treated to no one being treated, as illustrated in Figure 1. The naive
methods are additive regression analyses that do not properly correct for time-
dependent confounding. In the first naive method we control for both treatment
and covariate, and in the second we only control for treatment.
All of the methods are different implementations of Aalen’s additive hazards
regression models, and we are interested in estimating the effect of treatment on
survival. The estimated effects are displayed as curves showing the differences
in cumulative hazards between the treated and untreated.
For the simulations, there are no single target parameter we can compare
against to assess performance and check that methods are valid. Instead, we
include an analysis of a simulated full counterfactual dataset. This dataset is
constructed by combining data coming from the algorithm shown above where
treatment is offered, with data from the same algorithm, but without offering
treatment. This means that we end up with a dataset where those who originally
received treatment are also included with their untreated histories. Analysing
such a dataset with a univariable regression, controlling only for treatment,
yields an estimate of the average treatment effect on the treated (ATT). In the
simulation results, we will call this treatment effect on the treated: simulated.
Finally, we analyse the effect of treatment when starting treatment is ran-
domised. This corresponds to finding the average treatment effect (ATE). More
specifically, we implement a univariate regression, controlling only for treatment,
to a dataset generated the same way as earlier, but with a flat probability set
to 0.07 for starting treatment on all time points, for all individuals regardless
of covariate values. The value 0.07 was chosen so that the random treatment
setting was reasonably comparable to the other treatment regimes in terms of
proportions of the cohort starting treatment at some point during follow-up.
7.3 Simulation results for the additive model
Figure 8 shows the mean of the cumulative hazard differences for being on
treatment compared to not being on treatment. Both our proposed methods
for estimating ATT in Section 2.4 and Section 5, the red curve and the dotted
green curve, show similar estimates as the simulated target curve (blue) across
all treatment regimes.
Our methods estimate the treatment effect on the treated. This effect varies
between different treatment regimes. The marginal structural additive hazards
model on the other hand, gives more or less the same curve estimates across
the different regimes – estimates that are similar to the estimated treatment
effect in a randomised study, the black dotted curve. The naive method where
we control for both treatment and covariate value is estimating the direct effect
of treatment, which is constant across all three simulations (the purple curves).
The second naive method, green full-drawn line, where we only control for treat-
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Figure 8: Average cumulative coefficients for the treatment effect for the three
treatment regimes in the simulation study.
ment, behaves very different from the advanced methods. In all but the second
regime it fails to estimate a valid parameter, as it does not properly correct for
the time-dependent confounding that is strong in regime 1 and regime 3.
The simulations show how our proposed methods estimate treatment effects
that are dependent on who actually get treated. Given that we can impute
counterfactual covariate trajectories, the procedures succeed in estimating the
target curve that comes from analysing the full counterfactual dataset.
7.4 Simulation results for the Cox model
Treatment regime: 1 2 3
Treatment effect on the treated: simulated 0.77 0.74 0.69
Treatment effect on the treated: shortcut 0.79 0.75 0.68
Marginal structural model 0.75 0.74 0.75
Naive: treatment + time dependent covariate 0.93 0.93 0.91
Naive: treatment 0.84 0.76 0.64
Randomised treatment 0.75 0.75 0.75
Table 1: Cox model average hazard ratios for the effect of treatment.
Simulating data from Cox proportional hazards models with time-dependent
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confounding can be a very challenging task (Havercroft and Didelez, 2012), so
instead we use the data already simulated for the additive model where, in
contrary, simulation is very simple. This makes sense as it is quite clear that
the Cox model, as well as other models, typically are used for data where the
assumptions are not exactly fulfilled. In fact, one of the useful aspects of the
Cox model is its robustness towards many types of model deviations.
The results from applying a Cox based analysis to the data simulated in
Section 7 are presented in Table 1. We give all the same analyses as for the
additive model apart from that based on Equation (10). Hence, the various
settings are the same as previously and can be directly compared with the results
for the additive model. First, one can see (in lines 1 and 2) that estimating the
hazard ratio for the ATT using the shortcut approach gives essentially the same
results as when simulating the same scenario. This indicates that the estimation
method gives sensible results. In line 3 one sees that the marginal structural
Cox model result in a hazard ratio that is independent of the treatment regime,
as it should be, and that this fits with the randomised treatment (last line). The
ATT analysis gives weaker effects than the ATE from the marginal structural
model for regime 1, the same effect for regime 2, and stronger effects for regime
3. This again fits with the results for the additive model, and is as expected.
The naive analyses also have the same type of deviations as seen for the additive
model.
These are merely preliminary results, and obviously the issue of the validity
of our approach for the Cox model needs further clarification.
8 Discussion
We have presented a new approach for estimating the ATT under time-dependent
confounding. The ATT is a useful alternative to the ATE, and the two causal
estimands answer two different questions. The latter answers the question how
effective is the treatment if treatment was randomised over time?’, while the
ATT answer the slightly different question of how effective was treatment for
those who received it at the time they did? This is a subtle, but important
difference, and it is not given that one should automatically use one method or
the other when analysing data with time-dependent confounding – it depends
on what questions one asks.
The ATT is a relevant parameter, both in a clinical and epidemiological
setting, and quantifies the average effect of treatment as it was actually given.
In other words; it quantifies the effect of the current treatment policy and not
hypothetical ones. The ATT is often claimed to be a more relevant and preferred
effect measure than the ATE in settings with selection among treated patients
(Li et al., 2014). This is obviously the case in situations with time-dependent
confounding, such as in the application to the Swiss HIV Cohort Study. The
ATT for HIV treatment has been the target parameter in both early (Robins
et al., 1992; Hernán et al., 2005) and recent papers (Wallace et al., 2016) using
g-estimation. In settings were both the ATE and ATT can be identified, such
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as in our application, estimating both and comparing them will also add to the
overall knowledge of the treatment effect. A difference between the two effect
measures gives an indication on the effect of the current treatment policy.
Using the additive model gives an explicit derivation of the ATT in terms
of counterfactual covariate processes. The positivity assumption is not as strict
as when estimating the ATE, e.g. using inverse probability weighted marginal
structural models, because there is no requirement that each individual should
have a positive treatment probability. The no unmeasured confounding as-
sumption is however still central. This also goes for the linear increments model
when estimating counterfactual covariate processes, which we discussed earlier
in terms of assuming conditional exchangeability. Another important assump-
tion is the validity of the linear increments model itself. See VanderWeele (2013)
for more on sensitivity analysis of unmeasured confounding in additive and pro-
portional hazards models and Brumback et al. (2004) for more on sensitivity
analysis with time-dependent confounding in HIV cohort studies.
Our approach for estimating the ATT also has the benefit of giving a detailed
picture of how treatment works on the time-dependent variables themselves, and
not only on the outcome. This of course comes at the cost of the assumptions
for using the linear increments model, but in the application to data from the
Swiss HIV Cohort Study we found that the this model provided stable and
plausible estimates of counterfactual covariate trajectories. We have then shown
that these estimates can be used to estimate the ATT in the presence of time-
dependent confounding in survival data, by imputation in the additive hazards
model. This can be seen as a front-door type of approach (Pearl, 2009), where
causal effects are identified by estimating mechanisms, and our method may
therefore also give additional insight into the dynamics of how treatment works.
Note that in our use of the linear increments model, the counterfactual
covariate trajectories are only estimated until an individual experiences an event
or is censored, as it can be seen in Figure 5. Covariate values beyond such
events are not needed in order to fit our model for the overall treatment effect.
However, for the sake of studying the effects of treatment initiation on the time-
varying covariates themselves (and not on the main outcome) later covariate
values might be useful. In that case, the linear increment model can be used
to estimate covariate values after the time of censoring (or after the time of an
event in the more conceptual case of immortal cohorts). See e.g. Diggle et al.
(2007) for a further discussion of such topics.
Note also that the linear increments model is only one of many possible mod-
els that could be used for modelling of counterfactual covariate trajectories. Our
approach could equally be used with other methods. Models that describe the
progression of a specific disease using differential equations are another option,
such as the HIV model in Prague et al. (2013). Different models, including a
version of Farewell’s linear increments model, have also been compared in other
papers (Prague et al., 2016).
Compared to other methods that estimate the ATT under time-dependent
confounding on a time-to-event outcome our method is a two step approach,
where each step has the benefit of being easy to implement using two simple
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existing statistical software packages. The outcome model also have the benefit
of being a hazard regression model in the traditional sense, which typically is not
the case in the g-estimation approach. We believe that there are advantages in
considering several approaches for handling the thorny issue of time-dependent
confounding, and that the procedure described in this paper serve as a valuable
addition.
9 Acknowledgement
Jon Michael Gran, Rune Hoff and Odd O. Aalen were partly funded by the Re-
search Council of Norway, project numbers 191460 and 218368. Kjetil Røysland
was partly supported by the Norwegian Cancer Society contract/grant number
2197685.
References
Aalen, O. (1980) A model for nonparametric regression analysis of counting
processes. In Mathematical statistics and probability theory, 1–25. Springer.
Aalen, O., Røysland, K., Gran, J., Kouyos, R. and Lange, T. (2014) Can we
believe the dags? a comment on the relationship between causal dags and
mechanisms. Statistical methods in medical research, 0962280213520436.
Aalen, O. O. (1989) A linear regression model for the analysis of life times.
Statistics in medicine, 8, 907–925.
Aalen, O. O., Borgan, Ø. and Gjessing, H. K. (2008) Survival and event history
analysis: a process point of view. Springer.
Aalen, O. O. and Gunnes, N. (2010) A dynamic approach for reconstructing
missing longitudinal data using the linear increments model. Biostatistics,
11, 453–472.
Brumback, B. A., Hernán, M. A., Haneuse, S. J. and Robins, J. M. (2004) Sen-
sitivity analyses for unmeasured confounding assuming a marginal structural
model for repeated measures. Statistics in medicine, 23, 749–767.
Cole, S. R., Richardson, D. B., Chu, H. and Naimi, A. I. (2013) Analysis of
occupational asbestos exposure and lung cancer mortality using the g formula.
American journal of epidemiology, 177, 989–996.
Daniel, R., Cousens, S., De Stavola, B., Kenward, M. and Sterne, J. (2013)
Methods for dealing with time-dependent confounding. Statistics in medicine,
32, 1584–1618.
25
Didelez, V., Dawid, P. and Geneletti, S. (2006) Direct and indirect effects of
sequential treatments. In Proceedings of the Twenty-Second Conference An-
nual Conference on Uncertainty in Artificial Intelligence (UAI-06), 138–146.
Arlington, Virginia: AUAI Press.
Diggle, P., Farewell, D. and Henderson, R. (2007) Analysis of longitudinal data
with drop-out: objectives, assumptions and a proposal. Journal of the Royal
Statistical Society: Series C (Applied Statistics), 56, 499–550.
Edwards, J. K., McGrath, L. J., Buckley, J. P., Schubauer-Berigan, M. K.,
Cole, S. R. and Richardson, D. B. (2014) Occupational radon exposure and
lung cancer mortality: estimating intervention effects using the parametric
g-formula. Epidemiology, 25, 829–834.
Farewell, D. M. (2006) Linear models for censored data. Ph.D. thesis, University
of Lancaster.
Gran, J. M., Røysland, K., Wolbers, M., Didelez, V., Sterne, J. A., Lederger-
ber, B., Furrer, H., von Wyl, V. and Aalen, O. O. (2010) A sequential Cox
approach for estimating the causal effect of treatment in the presence of time-
dependent confounding applied to data from the Swiss HIV Cohort Study.
Statistics in Medicine, 29, 2757–2768.
Gunnes, N., Farewell, D. M., Seierstad, T. G. and Aalen, O. O. (2009a) Analysis
of censored discrete longitudinal data: estimation of mean response. Statistics
in Medicine, 28, 605–624.
Gunnes, N., Seierstad, T. G., Aamdal, S., Brunsvig, P. F., Jacobsen, A.-B.,
Sundstrøm, S. and Aalen, O. O. (2009b) Assessing quality of life in a ran-
domized clinical trial: Correcting for missing data. BMC medical research
methodology, 9.
Hansen, B. B. (2008) The prognostic analogue of the propensity score.
Biometrika, 95, 481–488.
Havercroft, W. and Didelez, V. (2012) Simulating from marginal structural
models with time-dependent confounding. Statistics in medicine, 31, 4190–
4206.
Hernán, M. A., Cole, S. R., Margolick, J., Cohen, M. and Robins, J. M. (2005)
Structural accelerated failure time models for survival analysis in studies with
time-varying treatments. Pharmacoepidemiology and drug safety, 14, 477–
491.
Hernán, M. A., McAdams, M., McGrath, N., Lanoy, E. and Costagliola, D.
(2009) Observation plans in longitudinal studies with time-varying treat-
ments. Statistical Methods in Medical Research, 18, 27–52.
26
Hoff, R., Gran, J. M. and Farewell, D. (2014) Farewell’s linear increments model
for missing data: The flim package. A peer-reviewed, open-access publication
of the R Foundation for Statistical Computing, 137.
Howe, C. J., Cain, L. E. and Hogan, J. W. (2015) Are all biases missing data
problems? Current Epidemiology Reports, 1–10.
Keil, A. P., Edwards, J. K., Richardson, D. R., Naimi, A. I. and Cole, S. R.
(2014) The parametric g-formula for time-to-event data: towards intuition
with a worked example. Epidemiology (Cambridge, Mass.), 25, 889.
Kennedy, E. H., Taylor, J. M., Schaubel, D. E. and Williams, S. (2010) The
effect of salvage therapy on survival in a longitudinal study with treatment
by indication. Statistics in medicine, 29, 2569–2580.
Li, Y., Schaubel, D. E. and He, K. (2014) Matching methods for obtaining sur-
vival functions to estimate the effect of a time-dependent treatment. Statistics
in biosciences, 6, 105–126.
Martinussen, T. and Vansteelandt, S. (2013) On collapsibility and confounding
bias in cox and aalen regression models. Lifetime data analysis, 19, 279–296.
Martinussen, T., Vansteelandt, S., Gerster, M. and Hjelmborg, J. v. B. (2011)
Estimation of direct effects for survival data by using the aalen additive haz-
ards model. Journal of the Royal Statistical Society: Series B (Statistical
Methodology), 73, 773–788.
Martinussen, T., Vansteelandt, S., Tchetgen, E. and Zucker, D. M. (2016)
Instrumental variables estimation of exposure effects on a time-to-event
response using structural cumulative survival models. arXiv preprint
arXiv:1608.00818.
Pearl, J. (2009) Causality: models, reasoning and inference. Cambridge Univ
Press.
Picciotto, S. and Neophytou, A. M. (2016) G-estimation of structural nested
models: Recent applications in two subfields of epidemiology. Current Epi-
demiology Reports, 3, 242–251.
Pirracchio, R., Carone, M., Rigon, M. R., Caruana, E., Mebazaa, A. and
Chevret, S. (2013) Propensity score estimators for the average treatment ef-
fect and the average treatment effect on the treated may yield very different
estimates. Statistical methods in medical research, 0962280213507034.
Prague, M., Commenges, D., Gran, J., Ledergerber, B., Furrer, H., Thiébaut,
R. et al. (2016) Dynamic versus marginal structural models for estimating the
effect of haart on cd4 in observational studies: application to the aquitaine
cohort study and the swiss hiv cohort study. Biometrics.
27
Prague, M., Commenges, D. and Thiébaut, R. (2013) Dynamical models of
biomarkers and clinical progression for personalized medicine: the hiv context.
Advanced Drug Delivery Reviews, 65, 954–965.
Robins, J. M., Blevins, D., Ritter, G. and Wulfsohn, M. (1992) G-estimation of
the effect of prophylaxis therapy for pneumocystis carinii pneumonia on the
survival of aids patients. Epidemiology, 319–336.
Robins, J. M. and Hernán, M. A. (2009) Estimation of the causal effects of
time-varying exposures. Longitudinal data analysis, 553–599.
Robins, J. M., Hernan, M. A. and Brumback, B. (2000) Marginal structural
models and causal inference in epidemiology. Epidemiology, 11, 550–560.
Røysland, K. (2012) Counterfactual analyses with graphical models based on
local independence. The Annals of Statistics, 40, 2162–2194.
Røysland, K., Gran, J. M., Ledergerber, B., von Wyl, V., Young, J. and Aalen,
O. O. (2011) Analyzing direct and indirect effects of treatment using dynamic
path analysis applied to data from the Swiss HIV Cohort Study. Statistics in
Medicine, 30, 2947–2958.
Seaman, S. R., Farewell, D. and White, I. R. (2016) Linear increments with
non-monotone missing data and measurement error. Scandinavian Journal of
Statistics.
Sterne, J. A., Hernán, M. A., Ledergerber, B., Tilling, K., Weber, R., Sendi, P.,
Rickenbach, M., Robins, J. M. and Egger, M. (2005) Long-term effectiveness
of potent antiretroviral therapy in preventing aids and death: a prospective
cohort study. Lancet, 366, 378–384.
Strohmaier, S., Røysland, K., Hoff, R., Borgan, Ø., Pedersen, T. and Aalen,
O. O. (2015) Dynamic path analysis-a useful tool to investigate mediation
processes in clinical survival trials. arXiv preprint arXiv:1504.06506.
Taubman, S. L., Robins, J. M., Mittleman, M. A. and Hernán, M. A. (2009)
Intervening on risk factors for coronary heart disease: an application of the
parametric g-formula. International Journal of Epidemiology, 38, 1599–1611.
Taylor, J. M., Shen, J., Kennedy, E. H., Wang, L. and Schaubel, D. E. (2014)
Comparison of methods for estimating the effect of salvage therapy in prostate
cancer when treatment is given by indication. Statistics in medicine, 33, 257–
274.
Tchetgen Tchetgen, E. J., Walter, S., Vansteelandt, S., Martinussen, T. and
Glymour, M. (2015) Instrumental variable estimation in a survival context.
Epidemiology, 26, 402–410.
The Swiss HIV Cohort Study (2010) Cohort profile: the Swiss HIV Cohort
Study. International journal of epidemiology, 39, 1179–1189.
28
VanderWeele, T. J. (2013) Unmeasured confounding and hazard scales: sen-
sitivity analysis for total, direct, and indirect effects. European journal of
epidemiology, 28, 113.
— (2015) Explanation in causal inference: methods for mediation and interac-
tion. Oxford University Press.
Vansteelandt, S., Joffe, M. et al. (2014a) Structural nested models and g-
estimation: The partially realized promise. Statistical Science, 29, 707–731.
Vansteelandt, S., Martinussen, T. and Tchetgen, E. T. (2014b) On adjustment
for auxiliary covariates in additive hazard models for the analysis of random-
ized experiments. Biometrika, 101, 237–244.
Vansteelandt, S. and VanderWeele, T. J. (2012) Natural direct and indirect
effects on the exposed: effect decomposition under weaker assumptions. Bio-
metrics, 68, 1019–1027.
Wallace, M. P., Moodie, E. E. and Stephens, D. A. (2016) Model assessment in
dynamic treatment regimen estimation via double robustness. Biometrics.
Westreich, D., Cole, S. R., Young, J. G., Palella, F., Tien, P. C., Kingsley, L.,
Gange, S. J. and Hernán, M. A. (2012) The parametric g-formula to estimate
the effect of highly active antiretroviral therapy on incident aids or death.
Statistics in medicine, 31, 2000–2009.
29
